Clinical trial
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent…
NCT00084825 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00084825 |
|---|---|
| Title | Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 |
| Official title | Crossover From Docetaxel and Placebo to Docetaxel and Imatinib in Patients With Androgen-Independent Prostate Cancer With Bone Metastases: Extension Trial to ID03-0008 |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Imatinib mesylate |
| Enrollment | 23 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Jun 11, 2004 |
| Last update posted | Oct 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: